Study S001904

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV - GL1DER HIV RCT

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07221214
Acronym: GL1DER HIV RCT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 200
Start: 2026-04-17
Primary completion: 2029-10-31
Lead sponsor: Vanderbilt University Medical Center
Conditions: HIV; Alcohol; Smoking Cigarette; Cardiovascular Disease Prevention
Interventions: DRUG:Semaglutide (Rybelsus®); DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:1P60AA032176

Registered primary outcomes

Average drinks/week past 30 days at 3 months [3 Months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.